Disposable E-Cigarette Use among U.S. Youth — An Emerging Public Health Challenge
Teresa W. Wang, Andrea S. Gentzke, Linda J. Neff, Emily Glidden, Ahmed Jamal, Eunice Park‐Lee, Chunfeng Ren, Karen A. Cullen, Brian A. King, Karen Hacker
Abstract
Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP). In this international platform trial, the control group used in the analysis was not restricted to patients who had undergone concurrent randomization, and both trial agents were reported to improve survival. This trial led some treatment guideline committees to recommend the use of these agents (www . cas . mhra . gov . uk/ ViewandAcknowledgment/ ViewAttachment . aspx?Attachment_id=103745). One cannot say with certainty that the statistical modeling was not successful in eliminating bias, especially in a complex and hard to understand platform trial such as REMAP-CAP. The added value from this trial relative to the other randomized trials with straightforward, comparable controls can be questioned.